Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 9 · below the Ichimoku cloud · RSI 48 · MACD above its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $62.3K | 0.00% | 10.80K | −89% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ALGS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ALGS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.4 | -12.9 | 5.7 | -19.4 | -4.8 | 1.2 | -26.7 | 38.5 | -3.9 | -2.1 | −40.9% | ||
| 2025 | -35.2 | -34.6 | -51.1 | -32.4 | -5.2 | 36.3 | 1.0 | 44.9 | -7.1 | -15.8 | 16.1 | -2.7 | −76.6% |
| 2024 | 3.9 | 43.5 | -1.0 | -21.9 | -22.9 | -40.7 | 48.6 | -2.5 | -31.7 | 12.9 | 160.8 | 56.2 | +140.0% |
| 2023 | 103.6 | -24.7 | -40.1 | 32.7 | -2.6 | -14.1 | -8.3 | -3.3 | -13.2 | -19.7 | 16.7 | -5.1 | −30.3% |
| 2022 | -73.1 | -24.1 | -11.2 | -45.1 | 9.3 | -6.2 | 2.5 | 0.8 | -12.0 | -4.5 | -4.8 | -4.7 | −92.0% |
| 2021 | 1.9 | 2.0 | -20.9 | 13.1 | 8.4 | -26.9 | -28.5 | 17.0 | -9.0 | 2.7 | -3.8 | -22.5 | −57.1% |
| 2020 | 25.2 | 47.8 | +85.1% |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Buy / hold / sell counts